Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00312702 · ClinicalTrials.gov registry record · Phase 1

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

A Phase 1 study of Malaria and Plasmodium Falciparum Malaria, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT00312702: Completed Phase 1 study of Malaria and Plasmodium Falciparum Malaria, sponsored by U.S. Army Medical Research and Development Command.

NCT00312702 is a Phase 1 study of Malaria and Plasmodium Falciparum Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 18 participants, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00312702, a Phase 1 study of Malaria and Plasmodium Falciparum Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.

Primary Outcome

An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe

Interventions

  • BIOLOGICAL Falciparum Malaria Protein 11 with AS02A adjuvant

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2006-04
Est. Completion 2007-04
Phase Phase 1

What the finished NCT00312702 record still lists

NCT00312702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Malaria appearing as the primary indexed condition, and to 1 intervention - of which Falciparum Malaria Protein 11 with AS02A adjuvant is the first listed.

NCT00312702 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00312702 about?

NCT00312702 is a clinical study titled "Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America". Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.

What is the current status of trial NCT00312702?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2007-04.

What conditions does trial NCT00312702 study?

This clinical trial studies the following conditions: Malaria, Plasmodium Falciparum Malaria.

What interventions are being tested in trial NCT00312702?

The interventions under investigation include: Falciparum Malaria Protein 11 with AS02A adjuvant (BIOLOGICAL).

Who is sponsoring clinical trial NCT00312702?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00312702 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00312702's enrollment target sits among peer trials

18 26th of 27 higher than 2 of 27 other Malaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00312702, the US trial registry maintained by the National Library of Medicine. NCT00312702 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.